Leukemia drug recognized by FDA as a breakthrough therapy

Share This Post

The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the treatment of adult patients with relapsed refractory FLT3-ITD acute myeloid leukemia ( AML ). This identification will accelerate the development of quizartinib and is expected to bring new drugs to patients as soon as possible.

AML is a malignant blood and bone marrow cancer that causes dysfunctional cancerous leukocytes to proliferate and accumulate uncontrollably, and affects the production of normal blood cells. The United States this year is expected to have more than 19000 name of the new diagnosed patients, and more than 10000 Ge AML deaths. The 2005-2011 survey results show that the 5- year survival rate of AML patients is only 26% , which is the lowest among all types of leukemia. FLT3 gene mutation is the most common genetic mutation in AML patients, while FLT3-ITD is the most frequent mutation of FLT3 gene, and about a quarter of AML patients carry this mutation. Compared with patients who did not carry this mutation, patients with FLT3-ITD mutations had a worse prognosis, a higher risk of cancer recurrence, and a greater risk of death after relapse. Even if these patients receive a hematopoietic stem cell transplant ( HSCT ), the chance of cancer recurrence after treatment is still higher than that of patients who do not carry this mutation. Currently, there is no approved treatment for this disease. Therefore, this breakthrough therapy is expected to bring new hope to patients with FLT3-ITD .

In addition to the breakthrough therapy identification, quizartinib also received FDA fast-track qualification for relapsed refractory AML therapy , and the orphan drug qualification for AML issued by FDA and the European Medicines Agency ( EMA ) . Quizartinib is still in the research and development stage and has not been approved in any country. Safety and tolerance have yet to be certified. However, this approval is expected to accelerate the development of the drug, which is really good news for patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟